BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:56 PM
 | 
Apr 08, 2008
 |  BC Extra  |  Company News

Endo withdraws Frova sNDA, ends Chronogesic deal

Endo (NASDAQ:ENDP) withdrew an sNDA for Frova frovatriptan tablets for the short-term prevention of menstrual migraine after evaluating the points raised in a not approvable letter from FDA. The selective serotonin (5-HT1B/1D) receptor agonist had met the primary endpoint of significantly improving the number of headache-free...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >